Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04338971 · ClinicalTrials.gov registry record · NA

Ipsihand Device Use in Stroke Patients to Assess Functional Motor Outcomes

A NA study of Stroke, sponsored by Neurolutions.

Completed
Registry status
NA
Development phase
24
Enrollment target
2
Study locations

NCT04338971: Completed NA study of Stroke, sponsored by Neurolutions.

NCT04338971 is a NA study of Stroke that has completed, run by Neurolutions. The registered enrollment target is 24 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04338971, a NA study of Stroke, has completed, sponsored by Neurolutions.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This study aims to evaluate the impact of the Neurolutions Upper Extremity Rehabilitation System, known as IpsiHand, on improving functional motor control for post-stroke patients with hemiparesis. The Neurolutions System is a brain-computer interface (BCI) comprised of a robotic orthosis, worn on the hand and wrist, and operated by the patient's brain waves which are measured by EEG electrodes. The system also utilizes a tablet interface to provide therapy instructions to the patient.

Conditions Studied

Interventions

  • DEVICE IpsiHand Therapy

Study Locations (2)

California

  • Neurolutions - Santa Cruz

Missouri

  • Neurolutions - St Louis

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-05-05
Est. Completion 2020-10-09
Phase NA

Sponsor

Neurolutions

2 total trials

What the Registry Record Tells You About NCT04338971

The ClinicalTrials.gov registry entry for NCT04338971 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Neurolutions, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which IpsiHand Therapy is the first listed.

NCT04338971 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Missouri.

Frequently Asked Questions

What is clinical trial NCT04338971 about?

NCT04338971 is a clinical study titled "Ipsihand Device Use in Stroke Patients to Assess Functional Motor Outcomes". This study aims to evaluate the impact of the Neurolutions Upper Extremity Rehabilitation System, known as IpsiHand, on improving functional motor control for post-stroke patients with hemiparesis. The Neurolutions System is a brain-computer interface (BCI) comprised of a robotic orthosis, worn on t...

What is the current status of trial NCT04338971?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-05-05. Estimated completion is 2020-10-09.

What conditions does trial NCT04338971 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT04338971?

The interventions under investigation include: IpsiHand Therapy (DEVICE).

Who is sponsoring clinical trial NCT04338971?

This trial is sponsored by Neurolutions, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04338971 being conducted?

This trial has 2 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.